Takeda Pharmaceutical Co Ltd (TAK)
13.19
+0.11
(+0.84%)
USD |
NYSE |
May 01, 16:00
13.27
+0.08
(+0.61%)
Pre-Market: 09:14
Takeda Pharmaceutical Revenue (TTM): 29.70B for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 29.70B |
| September 30, 2023 | 29.95B |
| June 30, 2023 | 29.99B |
| March 31, 2023 | 29.78B |
| December 31, 2022 | 30.06B |
| September 30, 2022 | 30.21B |
| June 30, 2022 | 30.63B |
| March 31, 2022 | 31.80B |
| December 31, 2021 | 31.55B |
| September 30, 2021 | 31.64B |
| June 30, 2021 | 31.39B |
| March 31, 2021 | 30.17B |
| December 31, 2020 | 29.98B |
| September 30, 2020 | 29.87B |
| June 30, 2020 | 30.00B |
| March 31, 2020 | 30.28B |
| December 31, 2019 | 29.70B |
| September 30, 2019 | 26.23B |
| June 30, 2019 | 22.53B |
| March 31, 2019 | 18.93B |
| December 31, 2018 | 16.12B |
| September 30, 2018 | 16.01B |
| June 30, 2018 | 16.05B |
| March 31, 2018 | 15.96B |
| December 31, 2017 | 15.92B |
| Date | Value |
|---|---|
| September 30, 2017 | 15.86B |
| June 30, 2017 | 16.03B |
| March 31, 2017 | 16.01B |
| December 31, 2016 | 15.95B |
| September 30, 2016 | 15.71B |
| June 30, 2016 | 15.39B |
| March 31, 2016 | 15.05B |
| December 31, 2015 | 15.13B |
| September 30, 2015 | 15.37B |
| June 30, 2015 | 15.86B |
| March 31, 2015 | 16.21B |
| December 31, 2014 | 16.47B |
| September 30, 2014 | 16.76B |
| June 30, 2014 | 16.75B |
| March 31, 2014 | 16.88B |
| December 31, 2013 | 16.94B |
| September 30, 2013 | 17.33B |
| June 30, 2013 | 18.05B |
| March 31, 2013 | 18.86B |
| December 31, 2012 | 19.68B |
| September 30, 2012 | 20.22B |
| June 30, 2012 | 19.72B |
| March 31, 2012 | 19.13B |
| December 31, 2011 | 18.43B |
| September 30, 2011 | 17.38B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
22.53B
Minimum
Jun 2019
31.80B
Maximum
Mar 2022
29.76B
Average
30.00B
Median
Jun 2020
Revenue (TTM) Benchmarks
| Hoya Corp | 5.537B |
| Astellas Pharma Inc | 10.99B |
| Nxera Pharma Co Ltd | 88.33M |
| PeptiDream Inc | 202.69M |
| Stemcell Holdings Inc | 9.984M |